Sponsored by:
Facebook (FB)
JP Morgan (JPM)
AutoZone (AZO)
Yahoo (YHOO)
Focus Stocks
Featured Stories
Medtronic Reports Fourth Quarter Earnings
Cracker Barrel Reports Earnings, Increases Guidance
Best ETFs For Facebook Exposure
Is Yum! Brands Closing in to Support?
Intuitive Surgical Bullish Signs
Teva to Present at the 30th Annual J.P. Morgan Healthcare Conference
Published on Monday, 09 January 2012 10:31 Written by TradersHuddle Staff
JERUSALEM-( Business Wire )-Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer, and William Marth, President & CEO, Teva Pharmaceuticals – Americas, will present on Tuesday, January 10, 2012.
What: Teva Presentation at the 30th Annual J.P. Morgan Healthcare Conference
Who: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd. &
William Marth, President and CEO, Teva Pharmaceuticals - Americas
When: Tuesday, January 10, 2012 at 9:30 a.m. (PST)
Where: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-presentations
or
http://jpmorgan.metameetings.com/webcasts/healthcare12/directlink?ticker=TEVA
How: Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s website.
About Teva
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 47,000 people around the world and reached $16.1 billion in net sales in 2010.
Related Articles
- New Ratings
- Teva - Traders Waiting for Entry
- Will Teva recover?
- Teva’s Board of Directors Votes to Re-Elect Dr. Phillip Frost as Chairman of the Board
- Early Research Calls
- NASDAQ 100's Update, In focus: PCLN, NFLX, GILD, VRTX, TEVA
- Teva Issues Updated Conference Call Information for First Quarter 2012 Financial Results on May 9, 2012
- Teva Reports First Quarter 2012 Results
- Teva Appoints Michael Hayden as President of Global Research and Development and Chief Scientific Officer
- Teva settles Nuvigil litigation with Mylan
Related Partner Headlines
- Teva's Board of Directors Votes to Re-Elect Dr. Phillip Frost as Chairman of the Board - Benzinga
- Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug Application for CEP-32496, A Novel BRAF(V600E) Inhibitor - Benzinga
- Teva Stock To Go Ex-dividend Tomorrow (TEVA) - TheStreet.com
- Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Loser - TheStreet.com
- UPDATE: Teva Posts Upbeat Q1 Profit, Declares Dividend - Benzinga
- Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Loser - TheStreet.com
- FDA Considering Letting Patients Purchase Drugs Without Prescriptions - Benzinga
- Teva Announces Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned to Teva's COPAXONE - Benzinga
- TEVA: QNASLTM Phase III Data Indicate Investigational Therapy with New Mode of Delivery has Positive Safety and Effective Profile - Benzinga
- Teva Announces Launch of Generic Prometrium Capsules in the United States - Benzinga
You could minimize risk by trading in stock sectors rather than individual stocks. Find out why ETFs are the hottest investment vehicle on the planet. Try ETF Profits for FREE NOW!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
